Intranasal immunisation of mice against Streptococcus equi using positively charged nanoparticulate carrier systems

Vaccine

Volumn 30, Issue 46, 2012, Pages 6551-6558

  Figueiredo, L ^a   Cadete, A ^a   Goncalves L M D ^a   Corvo, M L ^a   Almeida, A J ^a  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

Author keywords

Adjuvants; Chitosan; Liposomes; Nanoparticles; Nasal vaccines; Streptococcus equi

Indexed keywords

BACTERIAL ANTIGEN; CHITOSAN; CHOLESTEROL; GAMMA INTERFERON; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G2A; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 6; LIPOSOME; NANOCARRIER; NANOPARTICLE; OCTADECYLAMINE; PHOSPHATIDYLCHOLINE; TRIPOLYPHOSPHATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIBODY TITER; ARTICLE; CELL MEMBRANE; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; DRUG DELIVERY SYSTEM; ENCAPSULATION; FEMALE; GELATION; HUMORAL IMMUNITY; IMMUNIZATION; IMMUNOGENICITY; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PARTICLE SIZE; POLYACRYLAMIDE GEL ELECTROPHORESIS; PRIORITY JOURNAL; STREPTOCOCCUS EQUI; SURFACE CHARGE; TH1 CELL;

ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; CHITOSAN; DRUG CARRIERS; FEMALE; IMMUNOGLOBULIN A, SECRETORY; IMMUNOGLOBULIN G; INTERFERON-GAMMA; LIPOSOMES; LUNG; MICE; MICE, INBRED BALB C; NANOPARTICLES; STREPTOCOCCAL VACCINES; STREPTOCOCCUS EQUI; TH1 CELLS;

EID: 84867024503     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.08.050     Document Type: Article

References (47)

1. Harrington D.J., Sutcliffe I.C., Chanter N. The molecular basis of Streptococcus equi infection and disease. Microbes Infect 2002, 4:501-510.
2. Taylor S., Wilson W.D. Streptococcus equi subsp. equi (Strangles) infection. Clin Tech Equine Pract 2006, 5:211-217.
3. Waller A.S., Jolley K.A. Getting a grip on strangles: recent progress towards improved diagnostics and vaccines. Vet J 2007, 173:492-501.
4. Timoney J.F., Qin A., Muthupalani S., Artiushin S. Vaccine potential of novel surface exposed and secreted proteins of Streptococcus equi. Vaccine 2007, 25:5583-5590.
5. Timoney J.F. Equine strangles: 1999. AAEP Proc 1999, 45:31-37.
6. Vicente S., Prego C., Csaba N., Alonso M.J. From single-dose vaccine delivery systems to nanovaccines. J Drug Del Sci Tech 2010, 20:267-276.
7. Heurtault B., Frich B., Pons F. Liposomes as delivery systems for nasal vaccination: strategies and outcomes. Expert Opin Drug Deliv 2010, 7:829-844.
8. Azevedo A.F., Galhardas J., Cunha A., Cruz P., Gonçalves L.M.D., Almeida A.J. Microencapsulation of Streptococcus equi antigens in biodegradable microspheres and preliminary immunisation studies. Eur J Pharm Biopharm 2006, 64:131-137.
9. Florindo H.F., Pandit S., Alpar H.O., Almeida A.J. New approach on the development of a mucosal vaccine against strangles: systemic and mucosal immune responses in a mouse model. Vaccine 2009, 27:1230-1241.
10. Florindo H.F., Pandit S., Lacerda L., Alpar H.O., Almeida A.J. The enhancement of the immune response against S. equi antigens through the intranasal administration of poly-e{open}-caprolactone-based nanoparticles. Biomaterials 2009, 30:879-891.
11. Guss B., Flock M., Frykberg L., Waller A.S., Robinson C., Smith K.C., et al. Getting to grips with strangles: an effective multi-component recombinant vaccine for the protection of horses from Streptococcus equi infection. PLoS Pathog 2009, 5:e1000584.
12. Florindo H.F., Pandit S., Gonçalves L.M.D., Alpar H.O., Almeida A.J. Streptococcus equi antigens adsorbed onto surface modified poly-e{open}-caprolactone microspheres induce humoral and cellular specific immune responses. Vaccine 2008, 26:4168-4177.
13. Florindo H.F., Pandit S., Gonçalves L.M.D., Videira M., Alpar O., Almeida A.J. Antibody and cytokine-associated immune responses to S. equi antigens entrapped in PLA nanospheres. Biomaterials 2009, 30:5161-5989.
14. Waller A.S., Paillot R., Timoney J.F. Streptococcus equi: a pathogen restricted to one host. J Med Microbiol 2011, 60:1231-1240.
15. Henriksen-Lacey M., Korsholm K.S., Andersen P., Perrie Y., Christensen D. Liposomal vaccine delivery systems. Expert Opin Drug Deliv 2011, 8:505-519.
16. Vangasseri D.P., Cui Z., Chen W., Hokey D.A., Falo L.D., Huang L. Immunostimulation of dendritic cells by cationic liposomes. Mol Membr Biol 2006, 23:385-395.
17. Joseph A., Itskovitz-Cooper N., Samira S., Flasterstein O., Eliyahu H., Simberg D., et al. A new intranasal influenza vaccine based on a novel polycationic lipid-ceramide carbamoyl-spermine (CCS) I. Immunogenicity and efficacy studies in mice. Vaccine 2006, 24:3990-4006.
18. Guy B., Pascal N., Françon A., Bonnin A., Gimenez S., Lafay-Vialon E., et al. Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine 2001, 19:1794-1805.
19. Arca H.ç., Günbeyaz M., Şenel S. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev Vaccines 2009, 8:937-953.
20. Esmaeili F., Heuking S., Junginger H.E., Borchard G. Progress in chitosan-based vaccine delivery systems. J Drug Del Sci Tech 2010, 20:53-61.
21. Amin M., Jaafari M.R., Tafaghodi M. Impact of chitosan coating of anionic liposomes on clearance rate, mucosal and systemic immune responses following nasal administration in rabbits. Colloids Surf B: Biointerfaces 2009, 74:225-229.
22. Corvo M.L., Cruz M.E., Crommelin D.J.A., Storm G. Superoxide dismutase entrapped in long-circulating liposomes: formulation design and therapeutic activity in rat adjuvant arthritis. Biochim Biophys Acta 2002, 1564:227-236.
23. Cadete A., Figueiredo L., Lopes R., Calado C.C., Almeida A.J., Gonçalves L.M. Development and characterization of a new plasmid delivery system based on chitosan-sodium deoxycholate nanoparticles. Eur J Pharm Sci 2011, 45:451-458.
24. Rouser G., Yamamoto A. Two-dimensional thin layer chromatographic separation of polar lipids and determination of phospholipids by phosphorus analysis of spots values obtained in quadruplicate determinations of different amounts of phosphorus. Lipids 1969, 5:494-496.
25. Wang C., Smith R.L. Lowry determination of protein in the presence of Triton X-100. Anal Biochem 1975, 63:414-417.
26. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
27. Khatri K., Goyal A.K., Gupta P.N., Mishra N., Mehta A., Vyas S.P. Surface modified liposomes for nasal delivery of DNA vaccine. Vaccine 2008, 26:2225-2233.
28. Chiou C.J., Tseng L.P., Deng M.C., Jiang P.R., Tasi S.L., Chung T.W., et al. Mucoadhesive liposomes for intranasal immunization with an avian influenza virus vaccine in chickens. Biomaterials 2009, 30:5862-5868.
29. Sharma S., Mukkur T.K., Benson H.A., Chen Y. Pharmaceutical aspects of intranasal delivery of vaccines using particulate systems. J Pharm Sci 2009, 98:812-843.
30. Bachmann M., Jennings G. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
31. Patel G.B., Zhou H., Ponce A., Chen W. Mucosal and systemic immune responses by intranasal immunization using archaeal lipid-adjuvanted vaccines. Vaccine 2007, 25:8622-8636.
32. Nixon D.F., Hioe C., Chen P.D., Bian Z., Kuebler P., Li M.L., et al. Synthetic peptides entrapped in microparticles can elicit cytotoxic T cell activity. Vaccine 1996, 14:1523-1530.
33. Huang Y., Donovan M. Large molecule and particulate uptake in the nasal cavity: the effect of size on nasal absorption. Adv Drug Deliv Rev 1998, 29:147-155.
34. Csaba N., Garcia-Fuentes M., Alonso M.J. Nanoparticles for nasal vaccination. Adv Drug Deliv Rev 2009, 61:140-157.
35. Thiele L., Rothen-Rutishauser B., Jilek S., Wunderli-Allenspach H., Merkle H.P., Walter E. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages?. J Control Release 2001, 7:545-555.
36. Foged C., Arigita C., Sundblad A., Jiskoot W., Storm G., Frokjaer S. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine 2004, 22:1903-1913.
37. Shahiwala A., Vyas T.K., Amiji M.M. Nanocarriers for systemic and mucosal vaccine delivery. Recent Pat Drug Deliv Formul 2007, 1:1-9.
38. Meehan M., Nowlan P., Owen P. Affinity purification and characterization of a fibrinogen-binding protein complex which protects mice against lethal challenge with Streptococcus equi subsp. equi. Microbiology 1998, 144:993-1003.
39. Chanter N., Ward C.L., Talbot N.C., Flanagan J.A., Binns M., Houghton S.B., et al. Recombinant hyaluronate associated protein as a protective immunogen against Streptococcus equi and Streptococcus zooepidemicus challenge in mice. Microb Pathogenesis 1999, 27:133-143.
40. Flock M., Jacobsson K., Frykberg L., Franklin A., Guss B., Flock J.I. Recombinant Streptococcus equi proteins protect mice in challenge experiments and induce immune response in horses. Infect Immun 2004, 72:3228-3236.
41. Flock M., Karlstrom A., Lannergard J., Guss B., Flock J.I. Protective effect of vaccination with recombinant proteins from Streptococcus equi subspecies equi in a strangles model in the mouse. Vaccine 2006, 24:4144-4151.
42. Andrews G.P., Laverty T.P., Jones D.S. Mucoadhesive polymeric platforms for controlled drug delivery. Eur J Pharm Biopharm 2009, 71:505-518.
43. Sriamornsak P., Thongborisute J., Takeuchi H. Liposome-based mucoadhesive formulations for oral delivery of macromolecules. Oral Delivery of Macromolecular Drugs 2009, 169-193. Springer, New York. A. Bernkop-Schnürch (Ed.).
44. Jacobs A.A., Goonerts D., Nuijten P.J.M., Hartford O.M., Foster T.J. Investigations towards an efficacious and safe strangles vaccine: submucosal vaccination with a live attenuated Streptococcus equi. Vet Rec 2000, 147:563-567.
45. Brgles M., Habjanec L., Halassy B., Tomasic J. Liposome fusogenicity and entrapment efficiency of antigen determine the Th1/Th2 bias of antigen-specic immune response. Vaccine 2009, 27:5435-5442.
46. Baca-Estrada M.E., Foldvari M., Snider M., Harding K., Kournikakis B., Babiuk L.A., et al. Intranasal immunization with liposome-formulated Yersinia pestis vaccine enhances mucosal immune responses. Vaccine 2000, 18:2203-2211.
47. Nakanishi T., Kunisawa J., Hayashi A., Tsutsumi Y., Kubo K., Nakagawa S., et al. Positively charged liposome functions as an efficient immunoadjuvant in inducing cell-mediated immune response to soluble proteins. J Control Release 1999, 61:233-240.